For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten™, the first and only nilotinib with no mealtime restrictions indicated for adult patients ...

There has been a lot of excitement since the launch. Not only is the drug extremely effective (people lose about 15 percent ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

The weight-loss jab Wegovy made its debut on June 4 2021 . It was the first new weight-loss drug to be approved by the US ...

New research, led by experts at the University of Nottingham, has found that certain types of medication used to treat ...

The study, which is published in eClinicalMedicine, looked at whether a type of diabetes medication, called GLP-1 receptor agonists (GLP-1 RAs), could ... Another study found that people taking the ...

ReShape Lifesciences Inc. ( NASDAQ: RSLS) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas Stankovich - CFO ...

Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe.

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) ...